口生殖器人乳头瘤病毒感染与疫苗：对未包含在疫苗中的高危和低危基因型的调查
Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines.
作者信息
Buttà Michela, Serra Nicola, Panzarella Vera, Fasciana Teresa Maria Assunta, Campisi Giuseppina, Capra Giuseppina
机构信息
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) "G. D'Alessandro", University of Palermo, 90133 Palermo, Italy.
Department of Surgical, Oncological and Oral Sciences (Dichirons), University of Palermo, 90133 Palermo, Italy.
出版信息
Vaccines (Basel). 2023 Sep 7;11(9):1466. doi: 10.3390/vaccines11091466.
Knowledge of human papillomavirus transmission from the genital tract to the oral mucosa remains unsatisfactory, with poor and often inconsistent literature results. The increase in HPV-associated oral malignancies prompts further analysis of the simultaneous detection of the virus in the two anatomical areas and on the identification of genotypes to be included in future vaccines. Therefore, in this retrospective study, we evaluated orogenital HPV concurrence, hrHPV, lrHPV and type-concordance in 337 samples, as well as the prevalence of the most common genotypes not included in HPV vaccines. Concurrence was found in 12.5% (31/248) of cases, hr-concordance in 61.3% (19/31) and lr-concordance in 12.9% (4/31). Finally, type-concordance was found in 32.3% (10/31) of concurrent infections. Regarding the identification of non-vaccine genotypes, the significantly prevalent genotypes in the anogenital area were HPV66 (12.6%, < 0.0001), HPV53 (11.1%, < 0.0001), HPV51 (8.7%, < 0.0001), HPV42 (8.2%, < 0.0001) and HPV68 (5.6%, = 0.0034) in women and HPV66 (14.6%, = 0.0058), HPV42 (12.2%, = 0.0428), HPV51 (12.2%, = 0.0428), HPV53 (12.2%, = 0.0428), HPV70 (12.2%, = 0.0428) and HPV73 (12.2%, = 0.0428) in men. Considering the results of our study, we recommend including the high-risk genotypes HPV51, HPV68, HPV53 and HPV66 in future HPV vaccine formulations.
人乳头瘤病毒从生殖道传播至口腔黏膜的相关知识仍不完善，文献结果质量不高且常常不一致。人乳头瘤病毒相关口腔恶性肿瘤病例的增加促使人们进一步分析在这两个解剖区域同时检测该病毒的情况，并确定未来疫苗中应包含的基因型。因此，在这项回顾性研究中，我们评估了337份样本中的口生殖器人乳头瘤病毒并发情况、高危型人乳头瘤病毒（hrHPV）、低危型人乳头瘤病毒（lrHPV）和型别一致性，以及未包含在人乳头瘤病毒疫苗中的最常见基因型的流行情况。在12.5%（31/248）的病例中发现了并发情况，高危型一致性为61.3%（19/31），低危型一致性为12.9%（4/31）。最后，在32.3%（10/31）的合并感染病例中发现了型别一致性。关于非疫苗基因型的鉴定，在女性的肛门生殖器区域中，显著流行的基因型为HPV66（12.6%，<0.0001）、HPV53（11.1%，<0.0001）、HPV51（8.7%，<0.0001）、HPV42（8.2%，<0.0001）和HPV68（5.6%，=0.0034）；在男性中，显著流行的基因型为HPV66（14.6%，=0.0058）、HPV42（12.2%，=0.0428）、HPV51（12.2%，=0.0428）、HPV53（12.2%，=0.0428）、HPV70（12.2%，=0.0428）和HPV73（12.2%，=0.0428）。考虑到我们的研究结果，我们建议在未来的人乳头瘤病毒疫苗配方中纳入高危基因型HPV51、HPV68、HPV53和HPV66。
Zotero 插件